Blog

Despite 330 products in pipeline, stem cell therapies still face commercial challenges – ETHealthWorld.com

Despite 330 products in pipeline, stem cell therapies still face commercial challenges
ETHealthWorld.com
While steady progress in clinical research and increasing evidence of product effectiveness are significant driving factors for growth in the stem cell therapies market, a number of obstacles remain before they become widely commercially viable
Stem Cell Therapies Still Facing Commercial ChallengesPharmaceutical Executive (press release) (registration) (blog)



all 2 news articles »

2016-07-22 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.